首页> 美国卫生研究院文献>Cancer Science >Biodistribution of Neocarzinostatin Conjugated to Chimeric Fab Fragments of the Monoclonal Antibody A7 in Nude Mice Bearing Human Pancreatic Cancer Xenografts
【2h】

Biodistribution of Neocarzinostatin Conjugated to Chimeric Fab Fragments of the Monoclonal Antibody A7 in Nude Mice Bearing Human Pancreatic Cancer Xenografts

机译:新carcarinostatin与单克隆抗体A7嵌合Fab片段在人类胰腺癌异种移植裸鼠中的生物分布。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, we conjugated chimeric Fab fragments of the monoclonal antibody (MAb) A7, which reacts with pancreatic cancers, to the antitumor drug neocarzinostatin (chA7Fab‐NCS) and intravenously injected 125I‐labeled chA7Fab‐NCS into nude mice bearing a human pancreatic cancer xenograft. We compared the tumor localization of 125I‐labeled chA7Fab‐NCS with that of conventional 125I‐labeled A7‐NCS, which was produced by conjugation of MAb A7 and NCS. 125I‐Labeled chA7Fab‐NCS accumulated in the tumor earlier than 125I‐labeled A7‐NCS, and significantly larger amounts of 125I‐labeled chA7Fab‐NCS had accumulated in the tumor 1 hour after injection. The results suggest that chA7Fab may be a suitable carrier for NCS in immunotargeting therapy against pancreatic cancer.
机译:在这项研究中,我们将与胰腺癌反应的单克隆抗体(MAb)A7的嵌合Fab片段与抗肿瘤药物新carcarinostatin(chA7Fab-NCS)缀合,并静脉注射 125 I-标记的chA7Fab-将NCS移植到携带人胰腺癌异种移植物的裸鼠体内。我们将 125 I标记的chA7Fab-NCS与常规 125 I标记的A7-NCS的肿瘤定位进行了比较,后者是由MAb A7和NCS结合产生的。 125 I-标记的chA7Fab-NCS在肿瘤中的累积时间早于 125 I-标记的A7-NCS,并且大量的 125 I-注射后1小时,标记的chA7Fab-NCS聚集在肿瘤中。结果表明chA7Fab可能是NCS在针对胰腺癌的免疫靶向治疗中的合适载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号